Owens & Minor, Inc., along with its affiliated entities, operates as a global provider of healthcare solutions, serving markets both within the ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $0.97 · Revenue $2.62B · 3 analysts
Est. EPS $1.16 · Revenue $2.75B · 1 analysts
Est. EPS $1.27 · Revenue $3.04B · 1 analysts
Est. EPS $1.42 · Revenue $2.51B · 1 analysts
EPS $-0.32 · Revenue $2.63B
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $2.8B | -74.2% | +125.2% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-1.1B | -203.5% | -1277.1% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | 0.0% | -100.0% | -100.0% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | +1.0% | +151.2% | -331.0% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -39.8% | -1075.7% | -511.6% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $0 | +100.0% | -130.4% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | 0.0% | +100.0% | -113.5% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | -69.5% | -118.4% | +91.8% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 0.58x | -46.4% | -16.7% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $2.5B | -47.3% | -12.8% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -14.24 vs 1.02 | -1496.1% | — | — |
| Revenue Surprise | $2.8B vs $2.8B | -0.2% | — | — |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Nov 10, 2020 | Lowry Michael Wayne | officer: SVP, Corporate Controller | Common Stock | D | 10,000 | $22.22 |
| May 11, 2020 | Henkel Robert J | director | Phantom Stock | A | 17,242 | — |
| May 11, 2020 | Henkel Robert J | director | Common stock | A | 10,000 | $7.29 |
Operator: Good morning, and thank you for standing by. Welcome to the Accendra Health Second Quarter 2026 Earnings Conference Call. Please be advised that today's conference call is being recorded. [Operator Instructions] I would now like to hand the conference call over to your first speaker today, Will Parrish, Vice President, Strategy, Corporate Development and Investor Relations. Will Parrish: Thank you, operator, and good morning, everyone. I'd like to welcome you to Accendra Health's second quarter earnings call. Our comments on the call will be focused on the financial results of the second quarter of 2026, all of which are included in today's press release. The press release, along with the second quarter 2026 supplemental slides, which we will refer to throughout the call are posted in the Investor Relations section of our website. Please note that during this call, we will make forward-looking statements that reflect the current views of Accendra Health about our business, financial performance and future events. The matters addressed in these statements are subject to risks and uncertainties, which could cause actual results to differ materially from those projected or implied here today. Our expectations, beliefs and projections are expressed in good faith, and we believe there is a reasonable basis for them. However, there can be no assurance that our expectations, beliefs and projections will result or be achieved. Please refer to our SEC filings for a full description of these risks and uncertainties, including the Risk Factors section of our annual report on Form 10-K and quarterly reports on Form 10-Q. Any forward-looking statements that we make on this call, in our earnings press release or in our supplemental slides are as of today, and we undertake no obligation to update these statements as a result of new information or future events, except to the extent required by applicable law. In our discussion today, we will refer to non-GAAP financial measures and believe they might help investors to better understand our performance or business trends. Information about these measures and reconciliations to the most comparable GAAP financial measures are included in our press release. Today, I'm joined by Ed Pesicka, Accendra Health's President and Chief Executive Officer; Jon Leon, the company's Chief Financial Officer; and Perry Bernocchi, the company's Chief Operating Officer. I will now turn the call over to Ed. Ed? Edward Pesicka: Thank you, Will. Good morning, everyone, and thank you for joining us on the call today. Before I dive into our second quarter results and the outlook for the balance of the year, I'd like to take a moment to address the announcement included in today's press release that I have informed the Board of Directors of my intention to retire by the end of 2026. The decision to retire is never easy. However, after considerations with my family and careful thought, I've decided that now is the right time. It …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Edward A. Pesicka | President, Chief Executive Officer & Director | USD 2,904,579 | Male | 1968 | Active |
Jennifer Stone | Executive Vice President & Chief Human Resources Officer | USD 1,677,073 | Female | 1971 | Active |
Andrew G. Long | Executive Vice President and Chief Executive Officer of Products & Healthcare Services Segment | USD 1,343,781 | Male | 1965 | Active |
Perry A. Bernocchi | Executive VP & COO | USD 1,292,011 | Male | 1959 | Active |
Heath H. Galloway | Executive Vice President, General Counsel & Corporate Secretary | USD 883,541 | Male | 1977 | Active |
Jonathan A. Leon | Executive Vice President, Chief Financial Officer & Corporate Treasurer | USD 764,562 | Male | 1967 | Active |
Michael Wayne Lowry | Senior Vice President, Corporate Controller & Chief Accounting Officer | USD 261,659 | Male | 1962 | Active |
Trudi Allcott | Director of Media Relations | — | — | — | Active |
Will Parrish | Vice President of Strategy of Corporate Development, & Investor Relations | — | — | — | Active |
LONDON, UK / ACCESS Newswire / July 13, 2026 / Orosur Mining Inc. (TSX.V:OMI)(AIM:OMI)(OTC PINK:OROXF) TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : OROSUR MINING INC 1b.
Orosur Mining Inc (AIM:OMI, TSX-V:OMI) said fresh drilling at its APTA prospect in Colombia has reshaped its view of the target, with the first new hole returning a broad gold intersection and opening three areas for follow-up. Hole MAP-106A returned 229.7 metres at 0.88 grams per tonne gold, including several higher-grade intervals: 6.85 metres at 2.15 g/t, 59.2 metres at 2.02 g/t, 7.65 metres at 7.07 g/t and 4.7 metres at 3.95 g/t.
Honda and the Honda USA Foundation Support Hundreds of Programs Expanding Opportunity Across the U.S. PR Newswire
LONDON, UK / ACCESS Newswire / June 1, 2026 / Orosur Mining Inc. ("Orosur" or "the Company") (AIM:OMI)(TSXV:OMI), a minerals explorer and developer with projects in Colombia and Argentina, advises that during May 2026, the Company issued 2,850,000 new common shares of no par value each ("Common Shares") following the exercise of 2,850,000 restricted stock units (as announced on 19 May 2026) and 2,206,000 Common Shares for a total consideration of Cdn$551,500 following the exercise of 2,206,000 warrants at a price of Cdn$0.25 from its block listing announced on 14 January 2026. For the purposes of the Disclosure Guidance and Transparency Rules, the Company has 401,005,074 Common Shares in issue.
LONDON, UK / ACCESS Newswire / May 19, 2026 / Orosur Mining Inc. ("Orosur" or the "Company") (TSXV:OMI)(AIM:OMI) announces that the Company has issued 2,850,000 Common Shares ("Shares") representing 0.72% of the Company's current issued share capital, following the exercise of 2,850,000 restricted stock units ("RSUs") by directors, officers, and consultants of the Company. All of the Directors will be retaining their Shares and not selling after exercise, other than Thomas Masney, one of the Company's Non-Executive Directors, who will sell 75,000 Shares to cover the tax due on the Shares issued to him.
